Find stats on top websites
Barricaid, developed by Intrinsic Therapeutics, is a bone-anchored implant designed to reduce the risk of reherniation following discectomy surgery for lumbar disc herniations. The implant aims to close large annular defects, promoting healing and preventing future disc material from escaping. Barricaid is FDA-approved and clinically proven to reduce reherniation and reoperation rates.
Company : Intrinsic Therapeutics
Industry : Medical DevicesSpine HealthBiotechnology
Intrinsic Therapeutics Key Value propositions
Intrinsic Therapeutics Latest news
Technology - Barricaid
The reason is Barricaid, a pioneering annular closure device (ACD) that has demonstrated significant benefits through more than a decade of clinical research ...
Can Exercise Cure a Herniated Disc?
Jun 6, 2022 ... It is just as important to stop if you are noticing any new or increasingly severe discomfort. ... A new treatment, Barricaid, is a bone-anchored ...
ANNULAR CLOSURE - Patient Education Brochure
This brochure will provide you with information about the Barricaid® Annular. Closure Device (ACD), also referred to as “Barricaid,” a new treatment intended.
How Long Is Recovery from a Discectomy?
Nov 3, 2021 ... It's also important to follow the post-procedure instructions you'll be given. ... Fortunately, there's a new treatment available: Barricaid.
Intrinsic Therapeutics SWOT Analysis
Strengths
Clinically proven to reduce reherniation ratesFDA-approved productMinimally invasive procedure
Weaknesses
Limited market penetrationDependence on surgeon adoptionReimbursement challenges
Opportunities
Expand into international marketsDevelop new applications for the technologyPartner with hospitals and healthcare systems
Threats
Competition from other medical device companiesChanges in healthcare policyProduct liability lawsuits
Top Marketing Strategies for Intrinsic Therapeutics
Intrinsic Therapeutics User Persona
Name:
Age :
Gender :
Occupation :
Industry :
Education :
Preferred platforms
GOALS
Frustrations
Intrinsic Therapeutics Geographic and Demographic Insights
Geographic Insights: The United States is the primary market for Barricaid, representing a significant majority of users. Canada, Australia, the UK, and Germany constitute smaller, yet growing markets.
United States
90%
Canada
3%
Australia
2%
United Kingdom
1.5%
Germany
1%
Demographic Insights: Target users are primarily aged 35-64, with a slightly higher representation of females. This aligns with the demographics of individuals experiencing age-related spinal issues.
Intrinsic Therapeutics Socio-economic Profile
Household and Income Insights: Target users typically fall within middle-income brackets and have an average household size of 2-4 members, reflecting typical family structures.
Educational and Employment Insights: The majority of users are employed full-time or are business owners, suggesting a focus on individuals seeking to maintain their careers. Most possess a University or College level education.
Intrinsic Therapeutics Behavioral Insights
Interest-Based Insights: Target users show interest in physical therapy, pain management, spine health, a healthy lifestyle, fitness, nutrition, and back pain support groups.
Technology and Social Media Usage: Users are active on social media, particularly Facebook, YouTube, and Instagram. They primarily use desktops, followed by Android and iOS devices.
Intrinsic Therapeutics Top Competitors
Competitor | Estimated market share | Top domains |
---|---|---|
Centinel Spine | 35.2% | Spinal Implants, Motion Preservation, Minimally Invasive Surgery |
NuVasive | 32.8% | Minimally Invasive Surgery, Spinal Instrumentation, Cervical Disc Replacement |
Zimmer Biomet | 32% | Joint Reconstruction, Trauma Care, Spine Products |